Eiko LifeSciences Limited, supplier of specialty chemicals and Active Pharmaceutical Ingredients (APIs), entered into a definitive agreement to acquire a 51% equity stake in SSM Formulations Private Limited. SSM is a pharmaceutical formulations company based in Hinganghat, Wardha. The strategic acquisition marks a major step in Eiko’s long-term growth strategy.
Strategic Move Toward a Fully Integrated Pharma Model
With this transaction, Eiko moves beyond its traditional role as a specialty chemicals and API supplier and transitions into a fully integrated pharmaceutical company with capabilities in Finished Dosage Forms (FDF). Moreover, the acquisition will be completed in a phased manner, aligned with Eiko’s ongoing strategic fundraising through warrants. This structure ensures financial discipline while supporting scalable growth.
WHO-GMP Facility Positioned for Expansion
SSM operates a WHO-GMP accredited manufacturing facility located on the Nagpur–Hyderabad National Highway. The facility spans 16,400 square metres, with a built-up area of 80,000 sq. ft., and remains expansion-ready, offering an additional 5,000 sq. ft. on the first floor. Importantly, the plant’s infrastructure supports rapid scale-up and compliance with global quality standards.
Significant Capacity Scale-Up Opportunity
Backed by Eiko’s strong marketing network, financial strength, and robust working capital base, the SSM facility has the potential to achieve an annual production capacity of 300 crore tablets and 90 crore capsules. As a result, SSM can scale its manufacturing operations and strengthen its presence in domestic and international formulation markets.
Leadership Commentary on Growth and Integration
Laxmikant Ramprasad Kabra, Director, Eiko LifeSciences Limited, stated, “This is not merely an acquisition—it creates a multiplier effect for Eiko. SSM Formulations brings a strong manufacturing base and an established presence in more than five international markets. By combining Eiko’s financial strength with SSM’s operational excellence, we intend to transform SSM into a global export hub”. He further added that Eiko aims to achieve 90% capacity utilisation in the near term, which is expected to drive significant topline and bottom-line growth for shareholders.
Phased Deal Structure Ensures Financial Prudence
Kabra highlighted the strategic structuring of the transaction. “By executing the deal progressively alongside our warrant issuance, we are maintaining financial prudence while securing a high-growth asset. SSM’s facility meets world-class standards, and when combined with Eiko’s chemical and API expertise, we will offer truly end-to-end pharmaceutical solutions—from molecule to medicine.”
Strengthening Global Pharma Ambitions
As reported by indianpharmapost.com, overall, the acquisition reinforces Eiko LifeSciences’ ambition to build a global pharmaceutical platform. By integrating APIs, specialty chemicals, and formulations under one umbrella, the company is positioning itself for sustained growth across regulated and emerging markets.
